Michael Henry Currer Williams MA BM BCh MRCP was the Medical Officer for the Dyestuffs and Pharmaceuticals Divisions of Imperial Chemical Industries Limited from 1947 to his death on 9 July 1961. When I joined ICI in 1972 his contributions to the field of occupational health and particularly the prevention of cancer in the chemical industry were still remembered and proved to be critical to development of occupational health policies and research in the Company. It is a great privilege, therefore, to deliver this lecture in his memory.
The first three lectures by Sir Charles Dodds", Professor E Boyland-and Professor RAM Case'' clearly described Michael Williams' contribution from first hand experience of having worked with him. His involvement in the preparation of a code of industrial practice to protect workers against chemical carcinogens was noted. His work in experimental chemical carcinogenesis, the early detection ofbladder cancer and the development of epoxide derivatives as cancer chemotherapeutic agents was discussed.
In particular it was his work with 4-aminobiphenyl that created his reputation within the Company. One of the uses for 4-aminobiphenyl was in the manufacture of an anti-oxidant for rubber". In the light of the carcinogenicity of structurally related chemicals, Williams and his co-workersf-" suspected that 4-aminobiphenyl would be carcinogenic. They conducted animal carcinogenicity studies which demonstrated that 4-aminobiphenyl was carcinogenic in rats and dogs and they forecasted that it would produce bladder tumours in man. Some years later it was shown to be carcinogenic in exposed workers in the USA.
A similar tragedy was avoided in the UK by Williams' insistence that 4-aminobiphenyl should not be used until it was tested for carcinogenicity in animals. These events also represent one of the first examples of a chemical identified on a structural basis and subsequently defined experimentally as a carcinogen prior to epidemiological evidence for its human effects becoming available.
In selecting the theme of my lecture I was struck by Michael Williams' interest in the use oflaboratory techniques for the prediction of carcinogenicity. I have therefore chosen to review the developments in carcinogen hazard assessment over the last 25 years highlighting examples of contributions made by ICI's laboratories.
Changes in toxicological practice
The research environment of the experimental toxicologist in the 1950s was substantially different from today. The protocols used in animal experiments were not rigidly defined by regulatory edict. Michael Williams' work involved subcutaneous injection of small numbers of animals over a short period of time. His conclusions were based on his own judgement putting into perspective any changes in tumour incidence which he did not consider relevant to man. At that time, the reliability of carcinogenicity studies carried out by subcutaneous injection or bladder implantation had been questioned. With regard to the mechanism of action of carcinogens, the role of mutagenesis was seen as just one of the number of competing theories."
Today carcinogenicity testing in animals involves larger numbers, high doses, longer times and more rigorous pathological and statistical evaluation. Data from two species and information on mutagenicity are often available. A response limited to tumours at the site of application is no longer considered to be a reliable indicator of carcinogenicity. Epigenetic mechanisms of cancer induction are still hotly debated.". : The increase. in information and changes in perspective The International Agency for Research into Cancer, in its monograph series on 'The Assessment of Carcinogenic Risks of Chemicals to Man' categorizes carcinogens into three groups. Group 1 includes chemicals, groups of chemicals or industrial processes, which are carcinogenic to humans. Group 2 represents those which are probably carcinogenic for humans; group 2A having a higher degree of evidence than group 2B. This categorization provides a useful framework for comparing the knowledge concerning human carcinogens in 1961 and 1987. Thus, using the 1987 listing I have applied the latest criteria to data available in 1961 (obtained from a literature review). The striking feature of the comparison was that the number of category 1 carcinogens due to occupational exposure has increased by relatively few over 25 years (from 11 to 14). In contrast, the number shown to be carcinogenic in animals and classified as category 2A or 2B had increased from 5 to 72. Possible reasons for this difference are: (i) epidemiological studies have a much lower power for detecting carcinogenicchemicals, because of difficulties in methodology (length of follow-up, size of cohorts, etc.), (ii) when exposure to carcinogenic chemicals has been controlled by good industrial hygiene animal carcinogenicity studies identifying potential human carcinogens have achieved their objective in preventative medicine, (iii) the 'carcinogens' included in the lower classification (2B),where the largest increase has occurred, are not human carcinogens and the animal studies are misleading. Whatever the reason for these changes, there is substantially more information available to protect the workforce from occupational cancer today.
In 1973 the Company reviewed its approach to handling chemical carcinogens and this led to (a) a review of all Company products in order to identify chemicals that might have carcinogenic properties, (b) the institution of an expert panel to assist in evaluating carcinogenicity data, (c) a research programme to improve methods of assessing carcinogenicity and (d) the implementation of a training and education programme on chemical carcinogenicity for managers in the Company. Of interest within the context of this paper is the research programme initiated in 1973 at the Central Toxicology Laboratory. The immediate problem was to develop a validated method for screening large numbers of chemicals and identifying those with potential carcinogenic properties so that their carcinogenicity could be evaluated and the necessary steps taken to protect those exposed.
Short-term predictive tests for carcinogens
The initiative taken within ICI coincided with a key publication entitled 'Carcinogens are mutagens: a single test system combining liver homogenates for activation and bacteria for detection" which represented a turning point in the field. In particular the assertion in the title of this paper that carcinogens are mutagens provided a new basis for developing screening tests for chemical carcinogens. Several groups embarked on validation studies to explore the association between carcinogenesis and mutagenesis.
In our laboratory a major validation exercise was mounted. Six test systems were chosen (Ames test, a cell transformation test, degranulation of endoplasmic reticulum, sebaceous gland suppression, tetrazolium reduction and subcutaneous implantation) and 120 chemicals were assessed in each system 10 . ll . Our work differed from others in a number of key ways: the chemicals were classified into carcinogens (58) and non-carcinogens (62) on the basis of published experimental data prior to their inclusion in the study. The assays were conducted without knowledge of the identities of the chemicals and six tests in parallel provided valuable comparative data.
Our main conclusion was that there was considerable variation between the performances of the different systems. The cell transformation test (developed by Dr J A Styles in our laboratory) and the Ames bacterial mutation test were the most accurate, each predicting carcinogenicity with greater than 90% accuracy. Moreover a combination of the results from these two tests provided an advantage over either test alone or any other combination of tests studied. It was concluded that the four other tests were of no general utility in screening for chemical carcinogens.
It was also evident that the outcome of the validation study depended to a large extent on the chemical class and biological activity of the chemicals selected as well as on the performance of the test system. Furthermore, the selection of eight carcinogen! non-carcinogen pairs provided information almost equivalent to that obtained from all the 120 chemicals used.
Another important observation was that all the test systems suffered from both false positive and false negative results, i.e. not all carcinogens were positive and not all non-carcinogens were negative. Clearly this has important implications when applying the results of validation studies of short-term tests to a consideration of their use for screening chemicals.
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Another serious practical problem occurs because the accuracy of a short-term test is affected by the prevalence of carcinogens amongst the sample of chemicals tested. In some cases structure activity relationships provide an important component of the assessment of the results. Ideally, the test chosen should be one which can detect structurally related carcinogens as positive and structurally related noncarcinogens as negative-e.
By 1980, about 10 validation studies of the Ames test had been reported-", the majority (8/10) demonstrating high sensitivity and specificity. A consensus was emerging that the Ames test was the most simple and accurate for screening chemicals for potential carcinogenicity. However, the problem of false positive and false negative results remained. For a screening test, false negative results were considered to be more serious and therefore a battery of tests which would be able to identify a wider range of chemical classes of carcinogens was felt desirable.
International validation studies
The ICI validation study gave us valuable experience in conducting and evaluating these studies. Key aspects of a successful study were the careful selection of pure compounds, with assessed biological spectrums, and the evaluation of chemicals without knowledge of their identity. By the late 1970s new test systems were being developed with increasing rapidity; by 1978 over 100 systems had been proposed"; A platform was needed for developing data on their performance on an international scale.
The first international validation study arose following discussions between the Health and Safety Executive in London and members of ICI Central Toxicology Laboratory. It evolved into a major international collaboration involving 65 laboratories". Forty-two chemicals were carefully selected on the principle of 'chemical class control pairs'. From an evaluation of the available animal carcinogenicity data the 42 chemicals were classified as 25 carcinogens and 17 non-carcinogens including 14 paired compounds. The main conclusions from this first international study were that the Ames assay remained the most robust, reliable and accurate of the in vitro microbial mutation assays. When complemented with mammalian cell in vitro assays a slight advantage in terms of sensitivity and specificity was obtained. Nevertheless, false positive and particularly false negative results continued to be a problem. Short term in vivo assays (mouse micronucleus, sperm morphology and chromosomal aberration tests) had high specificity but low sensitivity; hence they were not suitable as an initial screening test but could form a useful contribution in supplementing and confirming in vitro results.
Subsequently several studies aimed to clarify and extend these conclusions. The largest two, each involving about 90 laboratories from around the world, were sponsored by the International Program for Chemical Safety. Dr John Ashby took a leading role in study design and interpretation16.
From these validation studies and the practical experience of scientists screening chemicals it appears that a simple stepwise screening procedure can provide adequate prediction of mammalian carcinogenicity. The most common approach used in industrial laboratories is to screen chemicals using the Ames and in vitro cytogenetic assays. With negative results in both of these assays it can be assumed that the chemical is non-genotoxic. However, if a positive result is obtained in one or both assay systems, further testing is required. Some laboratories then use in vitro systems but in vivo systems such as the mouse bone marrow micronucleus assay and unscheduled DNA synthesis assay always form the final part of the test strategy. A further specialized test, e.g. DNA binding, may be required in specific instances. Similarly, data from heritable mutation assays or information on binding or chromosome abnormalities in spermatogonia may be required to assess the heritable effects of the chemical.
It is to be hoped that a simplified and internationally harmonized approach to the detection of possible human carcinogens and mutagens will be agreed by regulatory authorities.
Prediction of potency from the Ames test
The enthusiasm for the Ames test led to exaggerated claims for its performance. Ames and Hooper!" claimed that potency estimations from the Ames test could predict carcinogenic potency in mammals. This seemed an improbable hypothesis because of the many fundamental differences between in vitro mutagenicity methods and in vivo carcinogenicity assays. Thus a lively correspondence between Ames on the one hand and Ashby and Styles on the other unfolded in the scientific literature'<". In subsequent years the hypothesis was discredited when a review of nine studies comparing potency confirmed that there was no correlation of potency. Thus quantitative data from in vitro mutagenicity assays would not be useful in quantitative risk assessment-".
Non-genotoxic carcinogens
The development of tests for mutagenicity reinforced the concept that chemical interaction with DNA with subsequent development of mutations was the key event in chemical carcinogenesis. However, over the next few years carefully conducted mutagenicity studies highlighted certain exceptions. For example saccharin when administered to rats at high doses for prolonged periods of time produced bladder tumours but there was little evidence for its mutagenicity. Thus Ashby and co-workers'" proposed the terms genotypic carcinogen and epigenetic carcinogen, the latter term to describe chemicals such as saccharin. This represented a turning point in the scientific thinking about the mechanisms of action of chemical carcinogens and methods of screening. It is now considered that the genotoxic and cancer promoting activities of sodium saccharin which only become apparent at elevated dose levels are due to the significant contribution of the sodium ion to the overall composition of biological fluids 22 • The NTP data and its challenge to short-term tests In 1984, Shelby and Stasiewicz presented preliminary findings from four in vitro genotoxicity assays carried out on 70 chemicals which had been defined as noncarcinogenic after lifetime studies in both rats and mice 23 • For the first time an analysis of the performance of short-term tests was being undertaken using carcinogenicity results obtained from a single source (the NTP) and conducted to similar standards, 53<Jf of the non-carcinogens were found to be positive in at least one of the four tests. There may be a variety of reasons for this relatively high false positive rate 2 4, including the loss of specificity which accompanies an improvement in carcinogen sensitivity when a battery of in vitro tests is used 10 • 11 . Indeed assuming an assay system was about 85% accurate, it is possible to show by calculation that 50% of a group of non-carcinogens tested in four tests would be positive. It was concluded that in vitro genotoxicity assays only provide evidence of possible animal carcinogenicity but are not definitive of carcinogenicity.
Recently chemical structure, Salmonella mutagenicity and the extent of carcinogenicity among 222 chemicals tested for carcinogenicity by the NTP was extensively evaluated-". There was a strong association between an analysis of chemical structure and mutagenicity for both carcinogens and noncarcinogens. Thus it was possible to divide the chemicals into genotoxic and non-genotoxic classes. Seventy of the carcinogens were active in both rats and mice and/or in two or more tissues and 70% of these carcinogens were positive in the Salmonella mutagenicity assay. However, in a group of 45 single species, single tissue carcinogens only 39% were positive in the Salmonella mutation assay. Of the 83 non-carcinogens 30% were mutagenic to Salmonella confirming that a significant proportion of in vitro mutagens are non-carcinogenic, probably due to their non-absorption or preferential detoxification in vivo. The decreasing accuracy over the last 10 years of the Salmonella assay as a predictor of rodent carcinogenicity was explained by the change in the criteria for selecting test chemicals from consideration of structure to relative environmental importance. It was concluded that the screening of chemicals using structural analysis, a carefully selected core of genotoxicity assays and animal carcinogenicity studies limited to the male rat and female mouse would be capable of detecting the multiple species/sex/site carcinogens. Life-time studies in both sexes of rats and mice would be required to identify single species/ sex/site carcinogens which are of questionable relevance to man. In this study the unreliability of animal carcinogenicity data is overcome and arising from it new concepts in evaluation of carcinogenic hazard will undoubtedly occur.
The contribution of mechanistic studies to the assessment of carcinogenic hazard The relevance of non-genotoxic mechanisms to human cancer risk assessment has become an important question. Most of the chemical industry has been screening development compounds using in vitro mutagenicity assays for the last 10 years or so. Thus the majority of chemicals reaching the later stages of development are non-genotoxic. Nevertheless. some of them produce cancer in experimental animals. Thus most chemicals found to be carcinogenic late in development are non-genotoxic carcinogens.
The suspicion that some routes of administration and some experimental techniques provided artefactual information with respect to chemical carcinogenicity has been around for some time. Repeated subcutaneous injection of some chemicals will produce local sarcomas; the fact that the same quantity of glucose injected subcutaneously in hypertonic solution would produce these sarcomas but not when injected in normotonic solution indicated that osmolarity was a key determinant of the responses". A response limited to local subcutaneous sarcomas after repeated injection is no longer considered to be a reliable indicator of carcinogenicity. Similarly, the implantation of glass beads will induce papillomas and carcinomas of the bladder. Weil and co-workers-? transplanted the bladder stones produced after administration of diethylene glycol from the treated animals to the control group. The cancers that subsequently developed were -restricted to those animals with bladder stones further demonstrating the unreliability of certain responses in laboratory animals.
In 1973 the identification of vinyl chloride as an occupational carcinogen led to a considerable amount of work in our laboratory on this and other chlorinated alkanes and alkenes. The work on three compounds summarized below exemplifies how detailed mechanistic studies can contribute to the subject of carcinogenic hazard assessment.
Hexachlorobutadiene (HCBD)
HCBD is a potent nephrotoxin and nephrocarcinogen. Green, Lock and others examined the mechanism by which HCBD produced its nephrotoxic activity'", A series of elegant studies demonstrated that HCBD is absorbed after oral administration and conjugated with glutathione in the liver. The glutathione conjugate is then excreted in the bile where it undergoes partial cleavage. The resulting HCBDcysteine conjugate is reabsorbed and reaches the kidney. It is cleaved by the enzyme {3-lyase to give a toxic thiol which causes localized kidney damage.
It was of interest to establish whether this mechanism of action could also explain its carcinogenic activity in the rat. HCBD is non-mutagenic in the standard Ames test. However, if rat kidney S-9 is used in the Ames test the cysteine-conjugate produces a positive result. Thus the thiol derived from the HCBDcysteine conjugate is strongly mutagenic and is most likely to be the proximate carcinogen responsible for the induction of renal carcinomas after the administration of HCBD.
This mechanistic study provided an explanation of why HCBD, a non-mutagen, is carcinogenic in animals.
In this case the inadequacy of the in vitro mutagenicity assay is responsible for the discrepancy in response.
Subsequently the in vitro nephrotoxicity and mutagenicity of the cysteine conjugates of HCBD, tetrafluoroethylene (TFE), hexafluoropropene (HFP), trichloroethylene and perchloroethylene were compared'", All five conjugates were toxic in vitro, an observation consistent with the known nephrotoxicity of three of them (HCBD, TFE and HFP). In addition all of the conjugates were activated by {3-lyase but only those of HCBD, trichloroethylene and perchloroethylene were mutagenic in the Ames test using rat kidney S-9. It can be assumed on this basis that, although TFE and HFP are nephrotoxins, they will not be carcinogenic to the kidney. This study identified a clear distinction between conjugates of chlorinated alkenes which were both nephrotoxic and mutagenic and those which were nephrotoxic but not mutagenic. An important consequence of this work was the provision of a mechanistic base for prediction of function on the basis of structure for halogenated alkenes.
Trichloroethylene
Trichloroethylene presented an interesting problem in that there was no evidence of genotoxicity or Journal of the Royal Society of Medicine Volume 82 May 1989 257 carcinogenicity in the rat, but it produced a high incidence of liver cancer in the mouse. This species difference in carcinogenic response formed the basis of a study of the mechanism of action of trichloroethylene aimed at assessing whether trichloroethylene would pose a potential carcinogenic hazard to man. Early studies/'' demonstrated that trichloroethylene administration produced a dramatic increase in liver weight in both rats and mice. Only in mice did it produce a dramatic increase in DNA synthesis and a substantial proliferation ofperoxisomes within the liver cells.
Trichloroethylene is metabolized to trichloroacetic acid in both rats and mice and this is the metabolite responsible for the peroxisome proliferation. An increased rate of trichloroacetic acid production results in peroxisome proliferation in the mouse'". Metabolism and peroxisome proliferating activity of trichloroethylene and trichloroacetic acid can be observed in rat and mouse liver cells in culture. Human cells in culture exhibit a much slower rate of metabolism of trichloroethylene to trichloroacetic acid and in addition trichloroacetic acid itself is incapable of inducing the proliferation of peroxisomes.
Thus the lack of hepatic carcinogenicity in the rat is a consequence of a slower rate of metabolism to trichloroacetic acid. In human cells there is both a slower metabolism to trichloroacetic acid and an inability to respond by peroxisome proliferation. These mechanistic studies lay the foundation for the conclusion that human liver will not be susceptible to the carcinogenic effects of trichloroethylene. Accordingly assessment of exposure to trichloroethylene should consider the responses in the liver in terms of a standard toxic response rather than a carcinogenic response.
Methylene chloride
Methylene chloride (at relatively high doses, 2000 and 4000 ppm) induces liver and lung cancer in mice but not in rats. It is mutagenic in vitro but not in vivo and can therefore be considered as a non-genotoxic carcinogen.
Risk assessment for exposure to methylene chloride presented a problem. Methylene chloride is metabolized by two routes, namely a cytochrome P·450 mediated metabolism and metabolism via glutathione conjugation. Green and co-workers's carried out a series of studies of comparative metabolism and pharmacokinetics, allowing the firm conclusion that the glutathione pathway is associated with the carcinogenic response. In the mouse at low doses the cytochrome P·450 pathway predominates. At doses above about 500 ppm this pathway is saturated and metabolism via the glutathione pathway predominates. This is the likely explanation for the carcinogenic response in mice at high dose levels. In rats and hamsters the markedly lower rate of metabolism via the glutathione pathway explains the lack of carcinogenic response in these two species.
In vitro studies confirm these interspecies differences in metabolic rate via the two pathways. Studies on human cells in culture have shown that metabolism by the cytochrome P-450 pathway does take place but at a much lower rate than even that of rats. Metabolism via the glutathione pathway occurs at a substantially slower rate than in any of the other species, indicating that man will be very much less susceptible to the carcinogenic activity of methylene chloride. Current work on the metabolism and pharmacokinetics of methylene chloride in different species is being used to refine a numerical risk assessment for human exposure.
The fact that methylene chloride appears to be a non-genotoxic carcinogen will lower the concern about its potential carcinogenicity, and indicates that the mechanistic approach and development of more refined models for risk assessment are applicable to both genotoxic and non-genotoxic carcinogens.
Risk assessment
A major thrust during the 1980s has been to provide quantitative estimates of risk of exposure to chemicals. The traditional approach of defining a noobserved effect level in an animal toxicology study and applying a safety factor of an arbitrary size does not match up to the technical precision and intellectual effort involved in toxicology studies and research into mechanisms of action of toxicants. New methods are being applied to the problem of quantitative risk assessment and toxicology can now be considered to have a single objective, namely that of contributing to an accurate assessment of risk once the exposure conditions are known. Research efforts in ICI and elsewhere are fundamental to the improvement of quantitative risk assessment of exposure to chemicals to man.
At this point it is interesting to reflect on Michael Williams' relatively simple and more subjective approach to assessing the risk of exposure to aromatic amine carcinogens'",
Epilogue
The role that Michael Williams played in the protection of health of workers within the Company was critical in establishing a philosophy in which this was considered a major management objective. He was the forerunner of a research team studying and developing improved methods of detecting chemical carcinogens. Latterly we have concentrated on refining and improving quantitative risk assessment by studies of mechanisms of action and the application of statistical methods of risk assessment. Weare indebted to Michael Williams for his pioneering work and the legacy he has left us of maintaining high standards in this important area.
In a paper of this length it was only possible to 
